Elaine Holmes

The invention relates to the field of viral diagnosis. In particular, it is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (a) determining in a sample of said subject the amount of at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (b) comparing the amount(s) of the at least one biomarkers determined in (a) with a reference, thereby diagnosing a viral infection.Further, the invention is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (A) determining in a sample of said subject the amount of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (B) comparing the amount of the ddhC determined in (A) with a reference, thereby diagnosing a viral infection; wherein the determination in (a) is done by NMR spectroscopy and the sample of the subject is a urine sample of said subject.The invention is also related to a diagnostic means for use in diagnosing a viral infection or a disease associated therewith, said diagnostic means comprising at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC), but also to a diagnostic means comprising 3′-deoxy-3′,4′-didehydro-cytidine (ddhC) for use in diagnosing a viral infection or a disease associated therewith, wherein the amount of the biomarker is determined done by NMR spectroscopy in a urine sample of a subject.Furthermore, the invention is directed to a device for diagnosing a viral infection or a disease associated therewith in a sample of a subject and to a kit for identifying a subject suffering from a viral infection or a disease associated therewith.

1H-NMR spectroscopic molecular markers are provided for identifying medical risk signatures such as SARS-CoV-2 infection, acute inflammation, or a cardiovascular risk condition. The markers use a combination of NMR intensity signals, including a Glyc signal from at least one N-acetyl (-NCOCH3) glycoprotein and an SPC signal from a choline head group (+N-(CH3)3) of a supramolecular phospholipids cluster (SPC) present in HDL and LDL lipoprotein subfractions. The Glyc signal is in a chemical shift region from ẟ = 2.00 ppm to ẟ = 2.20 ppm, and includes signals GlycA (2.00 ppm to 2.09 ppm) and GlycB (2.09 ppm to 2.2 ppm). The SPC signal is in a chemical shift region from ẟ = 3.20 ppm to ẟ = 3.30 ppm, and includes signals SPC1 (3.2 ppm to 3.235) ppm, SPC2 (3.235 ppm to 3.26 ppm), and SPC3 (3.26 ppm to 3.3 ppm). A system for identifying the markers is also provided.

This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

This invention pertains generally to the field of multivariate statistics, and in particular to new methods for the analysis (e.g., chemometrics) of chemical, biochemical, and biological data, including, for example, spectral data, including but not limited to nuclear magnetic resonance (NMR) spectral data. These methods are useful, for example, in metabonomics, proteomics, transcriptomics, genomics, etc., and form a part of other methods, for example, methods for the identification of chemical species, methods for the identification of biomarkers that are useful in methods of classification, diagnosis, prognosis, etc.